Adopted by the International Council for Harmonisation (ICH) in February 2026, the new ICH M15 guideline, titled “General Principles for Model-Informed Drug Development,” establishes foundational recommendations for the planning, evaluation, and documentation of evidence derived from model-informed drug development (MIDD). This guideline is pivotal as it aims to standardize practices across the pharmaceutical industry, promoting a more consistent approach to drug development that leverages advanced modeling techniques.
The introduction of ICH M15 comes at a time when the pharmaceutical sector is increasingly recognizing the value of data-driven methodologies in expediting drug development processes. By providing a structured framework, the guideline not only facilitates regulatory compliance but also enhances the ability of companies to make informed decisions throughout the drug development lifecycle. Stakeholders are encouraged to engage with the upcoming webinar on October 29, 2026, to better understand the implications of these guidelines on their operations and strategic planning.
Start your 7-day trial and see what the database can do →
